3K3A-APC (Dermatology)
Wound Healing / Dermatological Conditions
Pre-clinical/ResearchActive (Licensed)
Key Facts
Indication
Wound Healing / Dermatological Conditions
Phase
Pre-clinical/Research
Status
Active (Licensed)
Company
About ZZ Biotech
ZZ Biotech is a clinical-stage biotech firm developing 3K3A-APC, a genetically engineered variant of human activated protein C (APC) optimized for therapeutic use. Its lead program targets ischemic stroke, a condition with significant unmet medical need and a large market opportunity. The company has recently announced a licensing agreement for the dermatology application of 3K3A-APC, indicating platform versatility and a strategy to de-risk and monetize its asset through partnerships. As a private company, it remains pre-revenue and is focused on advancing its clinical pipeline.
View full company profile